Autres langues Fate Therapeutics, Inc.

Actions

FATE

US31189P1021

Recherche biotechnologique et médicale

Temps réel estimé Cboe BZX 15:52:10 02/10/2026			Varia. 5j.	Varia. 1 janv.
2,330 ^USD	+1,30%		-0,26%	+138,55%

25/09	Fate Therapeutics reçoit une subvention de 15 millions de dollars pour un essai de traitement contre le lupus	MT
09/09	Fate Therapeutics présente les données cliniques de FT819 et FT839 lors du congrès CCR West 2026	CI

Autres langues

13:00	Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
01/10	Fate Therapeutics to Participate in Upcoming Fourth Quarter 2026 Conferences
01/10	Fate Therapeutics to Participate in Upcoming Fourth Quarter 2026 Conferences
25/09	Fate Therapeutics Receives $15.0 Million California Institute For Regenerative Medicine CLIN2 Grant To Support Advancement Of RECLAIM-LN
25/09	Fate Therapeutics Receives $15 Million Grant for Lupus Treatment Trial
25/09	Fate Therapeutics Announces Receipt of California Institute for Regenerative Medicine (CIRM) CLIN2 Grant to Advance RECLAIM-LN
16/09	Fate Therapeutics Selected for Four Presentations Highlighting its Off-the-Shelf CAR T-Cell Portfolio in Autoimmune Disease at ACR Convergence 2026
10/09	Fate Therapeutics Announces Encore Clinical Data Presentation of FT819 Off-the-Shelf CAR T-Cell Product Candidate at the CCR - West 2026 Meeting
09/09	Fate Therapeutics Presents Clinical Data Of FT819 And FT839 At CCR ? West 2026 Meeting
09/09	Fate Therapeutics Announces Encore Clinical Data Presentation of FT819 Off-the-Shelf CAR T-Cell Product Candidate at the CCR – West 2026 Meeting
09/09	Fate Therapeutics Announces Encore Clinical Data Presentation of FT819 Off-the-Shelf CAR T-Cell Product Candidate at the CCR – West 2026 Meeting
03/09	Fate Therapeutics to Participate in Fireside Chat at the 2026 Annual Cantor Global Healthcare Conference
14/08	Fate Therapeutics Initiates Potentially Registrational Reclaim-Ln Clinical Trial of Ft819 for the Treatment of Lupus Nephritis
14/08	Fate Therapeutics Treats First Patient in Phase 2 Trial of FT819 for Lupus Nephritis
14/08	Fate Therapeutics Initiates Potentially Registrational RECLAIM-LN Clinical Trial of FT819 for the Treatment of Lupus Nephritis
13/08	Fate Therapeutics: Q2 Earnings Snapshot
13/08	Fate Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026
13/08	Fate Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates
04/08	Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - August 3, 2026
03/08	Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
09/07	Fate Therapeutics Shares Rise After FDA Clears Investigational New Drug Application for FT839
09/07	Fate Therapeutics Receives FDA Clearance Of Investigational New Drug Application For FT839 Product Candidate
09/07	Fate Therapeutics Gets US FDA Approval of Investigational New Drug Application for FT839 to Treat Autoimmune Diseases
09/07	Fate Therapeutics Receives FDA Clearance of Investigational New Drug Application for FT839 Product Candidate
06/07	Fate Therapeutics Presents Preliminary Clinical Data of FT819 Off-the-Shelf CAR T-Cell Product Candidate for Systemic Sclerosis At ISSCR 2026 Annual Meeting